Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Trillium Therapeutic (TRIL)

Trillium Therapeutic (TRIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,936,108
  • Shares Outstanding, K 104,995
  • Annual Sales, $ 150 K
  • Annual Income, $ -59,350 K
  • 60-Month Beta 2.08
  • Price/Sales 12,748.38
  • Price/Cash Flow N/A
  • Price/Book 8.50
Trade TRIL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings N/A on 11/12/21
  • Next Earnings Date 11/15/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00%
  • Historical Volatility 11.55%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +28.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.49 +5.43%
on 10/18/21
18.49 -0.27%
on 11/16/21
+0.94 (+5.37%)
since 10/15/21
3-Month
5.80 +217.93%
on 08/20/21
18.49 -0.27%
on 11/16/21
+12.05 (+188.58%)
since 08/16/21
52-Week
5.80 +217.93%
on 08/20/21
20.96 -12.02%
on 11/30/20
+3.34 (+22.12%)
since 11/16/20

Most Recent Stories

More News
Trillium Therapeutics Receives Final Court Order Approving Arrangement

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...

TRIL : 18.44 (+2.62%)
TRIL.TO : 23.33 (+0.47%)
PFE : 51.28 (-0.85%)
Trillium Securityholders Approve Acquisition by Pfizer

CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage...

TRIL : 18.44 (+2.62%)
TRIL.TO : 23.33 (+0.47%)
PFE : 51.28 (-0.85%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

GWB : 33.42 (-1.04%)
KDMN : 9.50 (+0.21%)
SIC : 14.49 (+0.07%)
TRIL : 18.44 (+2.62%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CXP, ECHO, INOV, TRIL; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 11, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CXP : 19.28 (+0.10%)
ECHO : 48.24 (+0.04%)
INOV : 41.06 (+0.17%)
TRIL : 18.44 (+2.62%)
Moore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law Firm

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning...

TRIL : 18.44 (+2.62%)
OPA : 9.96 (+0.10%)
HRC : 155.95 (+0.04%)
CXP : 19.28 (+0.10%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates LMRK, TRIL, LDL, FMBI; Shareholders are Encouraged to Contact the Firm

NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

LMRK : 16.33 (+0.18%)
TRIL : 18.44 (+2.62%)
LDL : 62.09 (+0.02%)
FMBI : 20.07 (-0.05%)
Trillium Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Trillium Therapeutics Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – TRIL

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Trillium Therapeutics Inc. (NASDAQ: TRIL) to Pfizer Inc. for $18.50 per share in cash is fair to Trillium shareholders....

TRIL : 18.44 (+2.62%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Trillium Therapeutics, Inc. Buyout

WILMINGTON, Del., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Trillium Therapeutics, Inc. (“Trillium”) (NASDAQ CM: TRIL ) regarding possible breaches...

TRIL : 18.44 (+2.62%)
TRILLIUM ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of TRIL and Encourages Investors to Contact the Firm

NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Trillium...

TRIL : 18.44 (+2.62%)
PFE : 51.28 (-0.85%)
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026

Palm Beach, FL – August 24, 2021 – FinancialNewsMedia.com News Commentary – Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense...

QBIO : 0.4625 (unch)
ABVC : 3.22 (+1.90%)
TRIL : 18.44 (+2.62%)
CASI : 0.8850 (+2.91%)
SESN : 1.0900 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin...

See More

Key Turning Points

3rd Resistance Point 19.34
2nd Resistance Point 18.91
1st Resistance Point 18.68
Last Price 18.44
1st Support Level 18.02
2nd Support Level 17.59
3rd Support Level 17.36

See More

52-Week High 20.96
Last Price 18.44
Fibonacci 61.8% 15.17
Fibonacci 50% 13.38
Fibonacci 38.2% 11.59
52-Week Low 5.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar